Barron’s bullish on Onyx; Invitrogen names integration team leader; Genta can resume trial

> Impressed by the market potential of Nexavar, an article in the influential financial publication Barron's points to the positive in Onyx Pharmaceuticals. Report

> Invitrogen has tapped Mark Smedley, its head of global operations, to head up the integration team in charge of handling the Applied Biosystems buyout. Report

> Genetic test maker Sequenom says it will sell 5.5 million shares to the public. Sequenom release

> MacAndrews & Forbes has agreed to supply up to $8 million in financing to Siga Technologies. Siga release

> Novartis has announced details of two new long-term outcome studies in its landmark Aspire Higher clinical trial program which has expanded to involve more than 35,000 patients in 14 trials. The newly-launched studies will evaluate the organ protection potential of the first-in-class direct renin inhibitor Rasilez, known as Tekturna in the US. Novartis report

> Apparently, it's not just a few activist Congressional reps who want doctors to fess up to payments from pharmaceutical companies. A new poll found that Americans want to know whether their physicians are getting gifts or payments from drugmakers. Report

> Seems like a match made in marketing heaven. Merck has been pushing its Gardasil vaccine--designed to prevent cervical cancer and genital warts by fending off the human papilloma virus--via ads in movie theaters showing Sex and the City. Gardasil report

> Pfizer said it isn't buying a majority stake in Ranbaxy Laboratories. Report

> Globalization and generic drugs: There's a collection of news today that illustrates a couple of trends that have taken firm hold in the drug-sales world, two trends that are inextricably linked. Report

> Some big stocks were down to multiyear lows last week--including Pfizer and Merck, a deveopment that runs counter to pharma's traditional position as a defensive stronghold. Pharma report

And Finally...Scientists have now isolated the "selfish" gene. Release

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.